GSMA: US Gets Set To Clash with Europe at WRC-19
24.10.2019 10:00:00 EEST | Business Wire | Press release
A clash between the US and Europe over 5G’s future development at The World Radiocommunication Conference 2019 (WRC-19) – taking place in Egypt from 28 October to 22 November 2019 – could risk $565bn of economic expansion globally over the next 15 years, warned the GSMA today.
This economic growth from next-generation 5G services depends on the availability of a specific strand of radio frequencies, known as ‘millimetre wave’ frequencies, which are set to be identified for use by mobile operators at WRC-19. However, efforts by Europe to constrain the use of these critical frequencies due to claims of potential interference with some space services has 5G’s future hanging in the balance.
“The stakes are high - a new generation of 5G services and the economic growth accompanying them will depend on the spectrum decisions taken at WRC-19,” said Brett Tarnutzer, Head of Spectrum, GSMA. “We are calling for Europe to join the US in taking a pro-5G stance at WRC-19 to protect its digital future. Some administrations are still determined to limit mobile use of airwaves that 5G requires to reach its full potential. This protectionist attitude will have consequences for our global economy if allowed to prevail.”
“Our focus is on ensuring that all regions are on board with the win-win resolution that will allow for robust 5G deployments globally while protecting satellite interests worldwide,” said Tom Power, Senior Vice President & General Counsel, CTIA. “Reports indicate that the fastest 5G peak speeds today are in the US, and that’s because the US was the first to deploy mmWave. The benefits of using this spectrum are clear but only through global harmonization at WRC-19 will all regions gain the greatest value.”
Benefits of mmWave spectrum
mmWave bands are critical to providing ultra-high speeds and ultra-high capacity for a wide range of consumer, business and government services that require almost instantaneous delivery of large amounts of data. This includes entertainment services such as downloading ultra-high definition movies in seconds, virtual and augmented reality applications, remote surgery with ‘haptic’ feedback, precise control of industrial devices and robots, and autonomous vehicles.
Three thousand delegates from over 190 nations will meet at WRC-19 to agree on how this spectrum may be used. Different countries may have different approaches and strategies, but WRC is the meeting point for all nations to maximize the potential for 5G within their borders by thinking globally. The process of harmonization at WRC-19 delivers global roaming and economies of scale for vendors and carriers, and that translates into lower costs, faster deployments and greater convenience for consumers.
Clash over airwaves at WRC-19
The build-up to WRC-19 is a four-year process and the use of mmWave spectrum has been the subject of intense technical study throughout. WRC-19 is the final decision after a lot of analysis and technical study.
Technical studies supported by the Americas, Africa and Arab states, have demonstrated that 5G using mmWave spectrum can co-exist safely and efficiently alongside weather-sensing services, commercial satellite services and others. These were conducted within the ITU, a UN agency. In the US, the FCC developed emission limits on 5G to protect weather sensors in nearby spectrum bands. Ahead of WRC-19, the FCC and the State Department also worked with regulators from other countries throughout the Americas, achieving consensus at the CITEL conference in Ottawa in August.
Despite this body of evidence, European countries are looking to limit the use of mmWave spectrum by setting protective technical conditions.
“It is important to follow studies which make realistic assumptions about how networks will function and make the best use of the spectrum for all,” added Brett Tarnutzer. This approach is being followed in the Americas, Africa and the Middle East but we need to find a global solution, including Europe. Large ‘guard bands’ will be needed – that is empty tranches of unused spectrum separating services - if we have technical limits which are too severe. This will restrict the economic benefit we can gain from finite spectrum resources and harm consumers and industry.”
-ENDS-
About the GSMA
The GSMA represents the interests of mobile operators worldwide, uniting more than 750 operators with over 350 companies in the broader mobile ecosystem, including handset and device makers, software companies, equipment providers and internet companies, as well as organisations in adjacent industry sectors. The GSMA also produces the industry-leading MWC events held annually in Barcelona, Los Angeles and Shanghai, as well as the Mobile 360 Series of regional conferences.
For more information, please visit the GSMA corporate website at www.gsma.com. Follow the GSMA on Twitter: @GSMA.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191024005025/en/
Contact information
Media Contacts:
For the GSMA
Gearóid Cashman
+44 79 7679 0169
gcashman@webershandwick.com
GSMA Press Office
pressoffice@gsma.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
